Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-Current Assets (2019 - 2025)

Vivos Therapeutics' Non-Current Assets history spans 7 years, with the latest figure at $20.8 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $20.8 million for Q4 2025, up 165.88% from a year ago — trailing twelve months through Dec 2025 was $67.6 million (up 111.65% YoY), and the annual figure for FY2025 was $20.8 million, up 165.88%.
  • Non-Current Assets for Q4 2025 was $20.8 million at Vivos Therapeutics, up from $19.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $20.8 million in Q4 2025 to a low of $5.2 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $8.2 million (2023), against an average of $9.6 million.
  • Peak annual rise in Non-Current Assets hit 165.88% in 2025, while the deepest fall reached 6.32% in 2025.
  • Year by year, Non-Current Assets stood at $6.4 million in 2021, then skyrocketed by 30.34% to $8.3 million in 2022, then dropped by 0.33% to $8.3 million in 2023, then fell by 5.54% to $7.8 million in 2024, then surged by 165.88% to $20.8 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $20.8 million, $19.9 million, and $19.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.